Cytarabine and Cardiac Failure Congestive - Suspected Cause

Rx drug information, pharmaceutical research, clinical trials, news, and more

Drugs By Name

By Condition

By Category

Actives

Index of reports > Cases with Cardiac Failure Congestive ()

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cytarabine where reactions include cardiac failure congestive. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Cytarabine side effects in

Reported by a physician from Germany on 2012-06-21

Patient:

Reactions: Alanine Aminotransferase Increased, Arrhythmia, Death, Neurotoxicity, Mucosal Inflammation, Lung Disorder, Aspartate Aminotransferase Increased, Cardiotoxicity, Cardiac Failure Congestive, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Granulocyte Colony Stimulating Factor
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia

Daunorubicin HCL
Dosage: induction 2; day 21-28
Indication: Acute Lymphocytic Leukaemia

Idarubicin HCL
Dosage: induction 1; day 1

Etoposide
Dosage: induction 1; day 1
Indication: Acute Lymphocytic Leukaemia

Cladribine
Dosage: between days 42-56; consolidation phase
Indication: Acute Lymphocytic Leukaemia

Cladribine
Dosage: between days 42-56; consolidation phase
Indication: Acute Myeloid Leukaemia

Cytarabine
Dosage: day 42-56 (0.5g/m2), consolidation phase
Indication: Acute Lymphocytic Leukaemia

Cytarabine
Dosage: induction 2; high dose; days 21-28

Idarubicin HCL
Dosage: induction 1; day 1

Etoposide
Dosage: induction 1; day 1
Indication: Acute Myeloid Leukaemia

Idarubicin HCL
Dosage: day 42-56; consolidation phase
Indication: Acute Myeloid Leukaemia

Granulocyte Colony Stimulating Factor
Dosage: induction 2; day 21-28
Indication: Acute Lymphocytic Leukaemia

Daunorubicin HCL
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia

Cytarabine
Dosage: day 42-56 (0.5g/m2), consolidation phase
Indication: Acute Myeloid Leukaemia

Cytarabine
Dosage: induction 2; high dose; days 21-28

Idarubicin HCL
Dosage: day 42-56; consolidation phase
Indication: Acute Lymphocytic Leukaemia

Fludarabine Phosphate
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia

Cytarabine
Dosage: induction 1; day 1

Mitoxantrone
Dosage: induction 2; day 21-28
Indication: Acute Lymphocytic Leukaemia

Mitoxantrone
Dosage: induction 2; day 21-28
Indication: Acute Myeloid Leukaemia

Fludarabine Phosphate
Dosage: induction 2; day 21-28
Indication: Acute Lymphocytic Leukaemia

Possible Cytarabine side effects in 87 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-02

Patient: 87 year old female, weighing 51.3 kg (112.9 pounds)

Reactions: Fluid Overload, Confusional State, Urinary Tract Infection, Anaemia, Syncope, Fungal Infection, Pleural Effusion, Hypoxia, Thrombocytopenia, Pathogen Resistance, Cardiac Failure Congestive

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Decitabine
    Dosage: 20 mg/m2, intravenous
    Indication: Acute Myeloid Leukaemia
    Start date: 2010-03-29
    End date: 2010-04-02

Decitabine
    Dosage: 20 mg/m2, intravenous
    Indication: Acute Myeloid Leukaemia
    Start date: 2010-02-27
    End date: 2010-03-03

Granulocyte Colony Stimulating Ractor (Granulocyte Colony Stimalating
    Dosage: 300 mg, subcutaneous
    Indication: Acute Myeloid Leukaemia
    Start date: 2010-02-27
    End date: 2010-03-03

Granulocyte Colony Stimulating Ractor (Granulocyte Colony Stimalating
    Dosage: 300 mg, subcutaneous
    Indication: Acute Myeloid Leukaemia
    Start date: 2010-03-29
    End date: 2010-04-02

Cytarabine
    Dosage: 20 mg/m2, subcutaneous
    Indication: Acute Myeloid Leukaemia
    Start date: 2010-02-27
    End date: 2010-03-03

Cytarabine
    Dosage: 20 mg/m2, subcutaneous
    Indication: Acute Myeloid Leukaemia
    Start date: 2010-03-29
    End date: 2010-04-02

Other drugs received by patient: Prilosec; Voriconazole; Neutra Phos (Neutra-Phos); Reglan; Potassium Chloride; Propranolol

Possible Cytarabine side effects in 79 year old male

Reported by a physician from Germany on 2012-04-16

Patient: 79 year old male, weighing 80.0 kg (176.0 pounds)

Reactions: Acute Myocardial Infarction, Cardiac Failure Congestive

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vidaza
    Dosage: 140mg daily
    Start date: 2011-11-30
    End date: 2011-12-04

Daunorubicin HCL
    Dosage: 90 milligram/sq. meter
    Start date: 2011-08-29
    End date: 2011-09-04

Vidaza
    Dosage: 140mg daily
    Start date: 2011-10-10
    End date: 2011-10-14

Cytarabine
    Dosage: 200 milligram/sq. meter
    Start date: 2011-08-29
    End date: 2011-09-04

Cytarabine
    Dosage: gram/sqm
    Start date: 2011-10-15
    End date: 2011-10-19

Cytarabine
    Dosage: 1900 milligram
    Start date: 2011-12-09
    End date: 2011-12-09

Cytarabine
    Dosage: 1900 milligram
    Start date: 2011-12-05
    End date: 2011-12-05

Vidaza
    Dosage: 75 milligram/sq. meter
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-08-24
    End date: 2011-08-28

Cytarabine
    Dosage: 1900 milligram
    Start date: 2011-12-07
    End date: 2011-12-07

Other drugs received by patient: Lenograstim; Torsemide; Pantoprazole; Tiotropium Bromide; Delix; Erythrocytes Transfusion; Platelets; Posaconazole; Ceftazidim; Azulfidine; Linezolid; Foradil; Sterofundin; Neupogen; Vergentan

Possible Cytarabine side effects in 79 year old male

Reported by a physician from Germany on 2012-03-15